ONCOLYTIC VIRUS FOR
MELANOMA
Ten years of approved clinical use. Durable complete responses at 10+ years. The staging-specific story β not the overall response rate β is where the clinical usefulness lives.
Staging-Specific Response Data
The OPTiM trial's overall 16.3% durable response rate understates the benefit in the population where T-VEC works best. Stage IIIB-IVM1a patients β unresectable non-visceral disease β had substantially higher durable response rates. Stage IVM1b/c patients with visceral involvement had lower rates. T-VEC addresses injected accessible lesions; visceral tumours can't be injected.
βT-VEC is a treatment for a specific situation β unresectable non-visceral disease with accessible injectable lesions β not a general metastatic melanoma treatment.β
T-VEC Administration and Response
Intratumoral injection into up to four accessible lesions per session. Initial dose 10βΆ PFU/mL, subsequent doses 10βΈ PFU/mL on day 1, day 15, then every two weeks. Response assessment at six months β initial lesion enlargement before regression is expected inflammatory response, not progression.
Combination with Pembrolizumab
62% ORR and 33% CR in Phase Ib/II first-line unresectable melanoma. Used at melanoma-specialised centres for PD-L1-negative tumours. Phase III primary endpoint not met, but CR durability drives continued use.
Combination with Ipilimumab
Phase II: 39% vs 18% ORR for combination versus ipilimumab alone. Anti-CTLA-4 addresses T-cell priming; viral oncolysis addresses antigen release.
Frequently Asked Questions
T-VEC for Melanoma
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Interested in Oncolytic Virus for Melanoma?
Upload your medical reports for a free evaluation. Our team will identify the most relevant oncolytic virus programmes and clinical trials for your specific diagnosis.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.